Lilly Crohn's disease med achieved sustained clinical remission and endoscopic response at two years

 More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment

Nearly 90% of patients who achieved endoscopic response at one year sustained it at two years

Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis

https://www.prnewswire.com/news-releases/most-patients-on-lillys-omvoh-mirikizumab-mrkz-for-crohns-disease-achieved-sustained-clinical-remission-and-endoscopic-response-at-two-years-302370878.html